[Glycemia and insulinemia after oral administration of Nomifensine].
Blood glucose and immunoreactive insulin (IRI) were evaluated in 8 healthy subjects after mg 200 of Nomifensina per os. 5 subjects underwent an oral glucose challenge before and after mg 200 of Nomifensine and their glucose and IRI were evaluated in both conditions. Nomifensine inhibits basal IRI but does not inhibit IRI levels after an oral glucose challenge. It is possible that nervous dopaminergic endings are present at the level of B cells.